CD70 and neoplasm: We thus first integrated the data from the Chinese DLBCL cohort, which includes WGS and WES data from 96 pairs of tumour/control samples and targeted sequencing data from 204 tumour‐only samples, to identify somatically occurring (tumour‐specific) mutations in CD70.